EPO: Cost-Effectiveness

• Thus, research presented to the Food and Drug Administration (FDA) supported a new target hematocrit range of 30-36%. (Current package insert)

• Hematocrit levels of 33-36% are associated with less risk of hospitalization and mortality.

Ma JZ et al. J Am Soc Nephrol 1999;10:610-619

Xia H et al. J Am Soc Nephrol 1999;10:1309-16.

Previous slide

Next slide

Back to first slide

View graphic version

Based on considerable research of the literature and discussions with a noted hematologist at the National Institutes of Health, HCFA is not able to confirm the allegations that there is a medical justification for maintaining sustained hematocrit levels above 36%

Program Memorandum. Intermediaries/Carriers. HCFA Pub 60 A/B. Rev. AB-97-8. 05-97. Retrieval Title: AB-97-8.60. SUBJECT: Hematocrit Levels for Erythropoietin (EPO)